Flori­da-based biotech with ap­proved car­dio­vas­cu­lar ther­a­py moves to go pub­lic via SPAC

A small com­mer­cial-stage biotech with one ap­proved ther­a­py for a rare dis­ease that caus­es high cho­les­terol is hop­ing to go pub­lic through a SPAC deal with Swift­merge.

The deal is still in the ear­ly stages, and a de­fin­i­tive merg­er agree­ment is ex­pect­ed in the sec­ond quar­ter of this year.

HDL Ther­a­peu­tics’ ap­proved ther­a­peu­tic de­vice, called the PDS-2 Sys­tem, us­es pa­tients’ own plas­ma to cre­ate nat­ur­al pre-β HDL, a form of cho­les­terol that can re­duce plaque and the risk of car­dio­vas­cu­lar prob­lems. The PDS-2 Sys­tem is ap­proved for re­duc­ing coro­nary athero­ma in ho­mozy­gous fa­mil­ial hy­per­c­ho­les­terolemia (HoFH) pa­tients, and HDL said it can be used with oth­er lipid-low­er­ing agents.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER